AbbVie Inc (ABBV)vsCareDx Inc (CDNA)
ABBV
AbbVie Inc
$253.35
+4.20%
HEALTHCARE · Cap: $447.62B
CDNA
CareDx Inc
$28.82
-3.76%
HEALTHCARE · Cap: $1.20B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 15117% more annual revenue ($62.82B vs $412.82M). ABBV leads profitability with a 5.8% profit margin vs -2.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CDNA
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.3%
Fair Value
$146.22
Current Price
$253.35
$107.13 premium
Margin of Safety
+57.7%
Fair Value
$46.59
Current Price
$28.82
$17.77 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Revenue surging 39.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 1.5%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity. Revenue growth of 39.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : CDNA
The primary concerns for CDNA are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while CDNA is a hypergrowth play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.48 — expect wider price swings.
CDNA is growing revenue faster at 39.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 37/100) and 12.4% revenue growth. CDNA offers better value entry with a 57.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?